taurine has been researched along with Acute Confusional Senile Dementia in 61 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "An attempt has been made to explore the possible role of Taurine in cataractogenesis." | 7.72 | Studies on protein and taurine in normal, senile and diabetic cataractous human lenses. ( Anthrayose, CV; Shashidhar, S, 2004) |
| "An attempt has been made to explore the possible role of Taurine in cataractogenesis." | 3.72 | Studies on protein and taurine in normal, senile and diabetic cataractous human lenses. ( Anthrayose, CV; Shashidhar, S, 2004) |
| "Tramiprosate has been found to inhibit β-amyloid oligomer formation by a multi-ligand enveloping mechanism of action that stabilizes Aβ42 monomers, resulting in the inhibition of formation of oligomers and subsequent aggregation." | 2.87 | Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease. ( Abushakra, S; Amedio, J; Hey, JA; Kaplan, PL; Kocis, P; Power, A; Tolar, M; Versavel, M; Yu, JY, 2018) |
| " Furthermore, in rat preclinical studies, 3-SPA displayed 100% oral bioavailability and 25% brain penetration, indicating that the metabolite is well absorbed and crosses the blood-brain barrier." | 2.87 | Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain. ( Abushakra, S; Hey, JA; Hort, J; Kocis, P; Power, A; Tolar, M; Vyhnálek, M; Yu, JY, 2018) |
| "Academic Alzheimer's disease centers, community-based memory clinics, and neuropsychiatric research sites." | 2.84 | Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential. ( Abushakra, S; Cummings, J; Gauthier, S; Hey, JA; Porsteinsson, A; Power, A; Sadowsky, C; Scheltens, P; Shen, L; Tolar, M; Vellas, B; Wang, P, 2017) |
| " While there were no statistically significant group differences in hippocampus volume using the First modeling approach, a significant dose-response reduction in hippocampus volume change was found in the Final models." | 2.74 | Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. ( Aisen, PS; Duong, A; Ferris, SH; Garceau, D; Gauthier, S; Haine, D; Lau, W; Oh, J; Sampalis, J; Saumier, D; Suhy, J, 2009) |
| "Responder rates for the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Mini-Mental State Examination (MMSE) were measured as improvement or absence of decline from baseline." | 2.72 | Vagus nerve stimulation in patients with Alzheimer's disease: Additional follow-up results of a pilot study through 1 year. ( Ben-Menachem, E; Blennow, K; C-son Silander, H; Ejnell, H; Jonsson, MA; Karlsson, M; Merrill, CA; Minthon, L; Nordlund, A; Rolstad, S; Sjögren, MJ; Warkentin, S, 2006) |
| " Only the highest doses of aducanumab and BAN2401 show modest efficacy, and higher dosing is limited by increased risk of vasogenic edema, especially in APOE4 carriers." | 2.66 | Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval. ( Abushakra, S; Hey, JA; Porsteinsson, A; Sabbagh, M; Tolar, M, 2020) |
| " The formation of toxic amyloid oligomers, extracellular amyloid plaques and amyloid angiopathy in brain by amyloid beta peptides are considered a part of the identified mechanism involved in disease pathogenesis." | 2.61 | Contributions of Mass Spectrometry to the Identification of Low Molecular Weight Molecules Able to Reduce the Toxicity of Amyloid-β Peptide to Cell Cultures and Transgenic Mouse Models of Alzheimer's Disease. ( Caba, IC; Luca, A; Mihai, CT; Stanciu, GD; Ştefănescu, R; Tamba, BI, 2019) |
| "Taurine is a key functional amino acid with many functions in the nervous system." | 2.61 | Roles of taurine in cognitive function of physiology, pathologies and toxication. ( Chen, C; Han, H; He, J; Lu, G; Xia, S; Xie, Z, 2019) |
| "Alzheimer's disease is the most common form of dementia, that affects millions of people worldwide." | 2.61 | Structure and Function of Alzheimer's Amyloid βeta Proteins from Monomer to Fibrils: A Mini Review. ( Agrawal, N; Skelton, AA, 2019) |
| "Tramiprosate is a glycosaminoglycan (GAG) mimetic designed to interfere with the actions of Abeta early in the cascade of amyloidogenic events." | 2.43 | Tramiprosate. ( Wright, TM, 2006) |
| "Taurine is frequently used in Alzheimer's disease models due to its protective effects." | 1.91 | Effects of taurine on metal cations, transthyretin and LRP-1 in a rat model of Alzheimer's disease. ( Aslan Karakelle, N; Dinçer, S; Tekin, E, 2023) |
| "Homotaurine is a potential therapeutic compound for treatment of Alzheimer's disease (AD), but its efficacy is still under investigation." | 1.72 | IL-33 and IL-10 Serum Levels Increase in MCI Patients Following Homotaurine Treatment. ( Banaj, N; Bossù, P; Golesorkhtafti, S; Lembo, M; Messina, B; Sireno, L; Spalletta, G; Toppi, E, 2022) |
| "Disease progression was investigated at 4 time points, from 9 to 18 months of age, and in 4 regions: cortex, hippocampus, striatum, and thalamus." | 1.72 | Spatio-temporal metabolic rewiring in the brain of TgF344-AD rat model of Alzheimer's disease. ( López-Gil, X; Muñoz-Moreno, E; Simões, RV; Soria, G; Tudela, R, 2022) |
| "In taurine-treated rats, superoxide dismutase activity was significantly (p < 0." | 1.62 | Taurine and Camel Milk Modulate Neurobehavioral and Biochemical Changes in Aluminum Chloride-Induced Alzheimer's Disease in Rats. ( Abdulkadir, TS; Ayo, JO; Dawud, FA; Isa, AS, 2021) |
| "With the surge in the cases of Alzheimer's disease (AD) over the years, several targets have been explored to curb the disease." | 1.56 | Dual targeting of cholinesterase and amyloid beta with pyridinium/isoquinolium derivatives. ( Chakravarty, H; Chen, WH; Ju, Y; Tam, KY, 2020) |
| "Taurine has been reported to have neuroprotective properties against dementia, including AD." | 1.56 | Evaluation of the neuroprotective effect of taurine in Alzheimer's disease using functional molecular imaging. ( Choi, JY; Han, SJ; Jeong, YJ; Kang, KJ; Lee, HJ; Lee, KC; Lee, YJ; Nam, KR; Oh, SJ, 2020) |
| " 3xTg-AD mice (10-month-old) were dosed intraperitoneally with 9R (daily 3, 10 or 30 mg/kg) for a month." | 1.56 | 9R, the cholinesterase and amyloid beta aggregation dual inhibitor, as a multifunctional agent to improve cognitive deficit and neuropathology in the triple-transgenic Alzheimer's disease mouse model. ( Ju, Y; Tam, KY, 2020) |
| "Tramiprosate is a small-molecule Aβ anti-aggregation agent that was evaluated in phase III clinical trials for AD but did not meet the primary efficacy endpoints; however, a pre-specified subgroup analysis revealed robust, sustained, and clinically meaningful cognitive and functional effects in patients with AD homozygous for the ε4 allele of apolipoprotein E4 (APOE4/4 homozygotes), who carry an increased risk for the disease." | 1.46 | Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data. ( Blennow, K; Fillit, H; Hey, JA; Kocis, P; Ray, S; Sinko, W; Tolar, M; Yu, J, 2017) |
| "Pretreatment of taurine significantly attenuated Aβ1-42-induced neuronal death." | 1.40 | Taurine attenuates amyloid β 1-42-induced mitochondrial dysfunction by activating of SIRT1 in SK-N-SH cells. ( Feng, G; Hu, H; Jia, N; Jin, H; Sun, Q; Wang, W, 2014) |
| "Taurine treatment rescued cognitive deficits in APP/PS1 mice up to the age-matching wild-type mice in Y-maze and passive avoidance tests without modifying the behaviours of cognitively normal mice." | 1.40 | Taurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer's disease. ( Cho, SM; Cho, Y; Kang, BR; Kim, HV; Kim, HY; Kim, JW; Kim, JY; Kim, Y; Lee, S; Woo, J; Yoon, JH, 2014) |
| "Taurine is an abundant aminoacid present in brain." | 1.34 | Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-beta-peptide aggregation. ( Avila, J; Hernández, F; Moreno, FJ; Santa-María, I, 2007) |
| " In consequence of these acute processes delayed cell death in the MBN and persistent loss of cholinergic fibre projections to the neocortex appear as early as 3 days following the Abeta-induced toxic insult." | 1.31 | beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. ( Abrahám, I; Harkany, T; Kónya, C; Korf, J; Laskay, G; Luiten, PG; Nyakas, C; Penke, B; Sasvári, M; Sebens, JB; Soós, K; Timmerman, W; Tóth, B; Zarándi, M, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.28) | 18.7374 |
| 1990's | 6 (9.84) | 18.2507 |
| 2000's | 15 (24.59) | 29.6817 |
| 2010's | 22 (36.07) | 24.3611 |
| 2020's | 16 (26.23) | 2.80 |
| Authors | Studies |
|---|---|
| Abdulkadir, TS | 1 |
| Dawud, FA | 1 |
| Isa, AS | 1 |
| Ayo, JO | 1 |
| Banack, SA | 1 |
| Stark, AC | 1 |
| Cox, PA | 1 |
| Toppi, E | 1 |
| Sireno, L | 1 |
| Lembo, M | 1 |
| Banaj, N | 1 |
| Messina, B | 1 |
| Golesorkhtafti, S | 1 |
| Spalletta, G | 1 |
| Bossù, P | 1 |
| Yildirim, C | 1 |
| Yar Saglam, AS | 1 |
| Guney, S | 1 |
| Turan, B | 1 |
| Ebegil, M | 1 |
| Coskun Cevher, S | 1 |
| Balabanli, B | 1 |
| Muñoz-Moreno, E | 1 |
| Simões, RV | 1 |
| Tudela, R | 1 |
| López-Gil, X | 1 |
| Soria, G | 1 |
| Zhang, Y | 2 |
| Guo, T | 2 |
| Ding, Y | 2 |
| Wang, X | 2 |
| Liu, P | 2 |
| Wu, DD | 1 |
| Liu, Y | 2 |
| Guan, W | 1 |
| Pan, J | 1 |
| Kuang, HX | 1 |
| Yang, BY | 1 |
| Tekin, E | 1 |
| Aslan Karakelle, N | 1 |
| Dinçer, S | 1 |
| Abyadeh, M | 1 |
| Yadav, VK | 1 |
| Kaya, A | 1 |
| McCarty, MF | 1 |
| O'Keefe, JH | 1 |
| DiNicolantonio, JJ | 1 |
| Tolar, M | 6 |
| Abushakra, S | 5 |
| Sabbagh, M | 2 |
| Chakravarty, H | 1 |
| Ju, Y | 2 |
| Chen, WH | 1 |
| Tam, KY | 2 |
| Mueed, Z | 1 |
| Mehta, D | 1 |
| Rai, PK | 1 |
| Kamal, MA | 1 |
| Poddar, NK | 1 |
| Hey, JA | 5 |
| Porsteinsson, A | 2 |
| Oh, SJ | 1 |
| Lee, HJ | 1 |
| Jeong, YJ | 1 |
| Nam, KR | 1 |
| Kang, KJ | 1 |
| Han, SJ | 1 |
| Lee, KC | 1 |
| Lee, YJ | 1 |
| Choi, JY | 1 |
| Zou, X | 1 |
| Himbert, S | 1 |
| Dujardin, A | 1 |
| Juhasz, J | 1 |
| Ros, S | 1 |
| Stöver, HDH | 1 |
| Rheinstädter, MC | 1 |
| Kocis, P | 3 |
| Yu, J | 1 |
| Sinko, W | 1 |
| Ray, S | 1 |
| Blennow, K | 3 |
| Fillit, H | 1 |
| Yu, JY | 2 |
| Versavel, M | 1 |
| Power, A | 3 |
| Kaplan, PL | 1 |
| Amedio, J | 1 |
| Scheltens, P | 1 |
| Sadowsky, C | 1 |
| Vellas, B | 2 |
| Cummings, J | 1 |
| Gauthier, S | 3 |
| Wang, P | 2 |
| Shen, L | 1 |
| Xu, LP | 1 |
| Wang, Q | 1 |
| Yang, B | 1 |
| Zhang, X | 1 |
| Hort, J | 1 |
| Vyhnálek, M | 1 |
| Chiquita, S | 1 |
| Ribeiro, M | 1 |
| Castelhano, J | 1 |
| Oliveira, F | 1 |
| Sereno, J | 1 |
| Batista, M | 1 |
| Abrunhosa, A | 1 |
| Rodrigues-Neves, AC | 1 |
| Carecho, R | 1 |
| Baptista, F | 1 |
| Gomes, C | 1 |
| Moreira, PI | 1 |
| Ambrósio, AF | 1 |
| Castelo-Branco, M | 1 |
| Ştefănescu, R | 1 |
| Stanciu, GD | 1 |
| Luca, A | 1 |
| Caba, IC | 1 |
| Tamba, BI | 1 |
| Mihai, CT | 1 |
| Chen, C | 1 |
| Xia, S | 1 |
| He, J | 1 |
| Lu, G | 1 |
| Xie, Z | 1 |
| Han, H | 1 |
| Agrawal, N | 1 |
| Skelton, AA | 1 |
| Hernández-Sánchez, A | 1 |
| Tejada-González, P | 1 |
| Arteta-Jiménez, M | 1 |
| Javed, H | 1 |
| Khan, A | 1 |
| Vaibhav, K | 1 |
| Moshahid Khan, M | 1 |
| Ahmad, A | 2 |
| Ejaz Ahmad, M | 1 |
| Tabassum, R | 1 |
| Islam, F | 2 |
| Safhi, MM | 1 |
| Sun, Q | 1 |
| Hu, H | 1 |
| Wang, W | 1 |
| Jin, H | 1 |
| Feng, G | 1 |
| Jia, N | 1 |
| Ding, K | 1 |
| Kim, HY | 1 |
| Kim, HV | 1 |
| Yoon, JH | 1 |
| Kang, BR | 1 |
| Cho, SM | 1 |
| Lee, S | 1 |
| Kim, JY | 1 |
| Kim, JW | 1 |
| Cho, Y | 1 |
| Woo, J | 1 |
| Kim, Y | 1 |
| Chumakov, I | 1 |
| Nabirotchkin, S | 1 |
| Cholet, N | 1 |
| Milet, A | 1 |
| Boucard, A | 1 |
| Toulorge, D | 1 |
| Pereira, Y | 1 |
| Graudens, E | 1 |
| Traoré, S | 1 |
| Foucquier, J | 1 |
| Guedj, M | 1 |
| Vial, E | 1 |
| Callizot, N | 1 |
| Steinschneider, R | 1 |
| Maurice, T | 1 |
| Bertrand, V | 1 |
| Scart-Grès, C | 1 |
| Hajj, R | 1 |
| Cohen, D | 1 |
| Brener, O | 1 |
| Dunkelmann, T | 1 |
| Gremer, L | 1 |
| van Groen, T | 1 |
| Mirecka, EA | 1 |
| Kadish, I | 1 |
| Willuweit, A | 1 |
| Kutzsche, J | 1 |
| Jürgens, D | 1 |
| Rudolph, S | 1 |
| Tusche, M | 1 |
| Bongen, P | 1 |
| Pietruszka, J | 1 |
| Oesterhelt, F | 1 |
| Langen, KJ | 1 |
| Demuth, HU | 1 |
| Janssen, A | 1 |
| Hoyer, W | 1 |
| Funke, SA | 1 |
| Nagel-Steger, L | 1 |
| Willbold, D | 1 |
| Habchi, J | 1 |
| Arosio, P | 1 |
| Perni, M | 1 |
| Costa, AR | 1 |
| Yagi-Utsumi, M | 1 |
| Joshi, P | 1 |
| Chia, S | 1 |
| Cohen, SI | 1 |
| Müller, MB | 1 |
| Linse, S | 1 |
| Nollen, EA | 1 |
| Dobson, CM | 1 |
| Knowles, TP | 1 |
| Vendruscolo, M | 1 |
| Rozga, M | 1 |
| Bittner, T | 1 |
| Höglund, K | 1 |
| Saumier, D | 4 |
| Aisen, PS | 3 |
| Ferris, SH | 2 |
| Duong, A | 3 |
| Suhy, J | 2 |
| Oh, J | 2 |
| Lau, W | 2 |
| Garceau, D | 4 |
| Haine, D | 3 |
| Sampalis, J | 3 |
| Martineau, E | 1 |
| de Guzman, JM | 1 |
| Rodionova, L | 1 |
| Kong, X | 1 |
| Mayer, PM | 1 |
| Aman, AM | 1 |
| Shitaka, Y | 1 |
| Mitani, Y | 1 |
| Nagakura, A | 1 |
| Miyake, A | 1 |
| Matsuoka, N | 1 |
| Caltagirone, C | 1 |
| Ferrannini, L | 1 |
| Marchionni, N | 1 |
| Nappi, G | 1 |
| Scapagnini, G | 1 |
| Trabucchi, M | 1 |
| Louzada, PR | 1 |
| Paula Lima, AC | 1 |
| Mendonca-Silva, DL | 1 |
| Noël, F | 1 |
| De Mello, FG | 1 |
| Ferreira, ST | 1 |
| Anthrayose, CV | 1 |
| Shashidhar, S | 1 |
| Wright, TM | 1 |
| Preskorn, SH | 1 |
| Borges, S | 1 |
| Flockhart, D | 1 |
| Merrill, CA | 1 |
| Jonsson, MA | 1 |
| Minthon, L | 1 |
| Ejnell, H | 1 |
| C-son Silander, H | 1 |
| Karlsson, M | 1 |
| Nordlund, A | 1 |
| Rolstad, S | 1 |
| Warkentin, S | 1 |
| Ben-Menachem, E | 1 |
| Sjögren, MJ | 1 |
| Briand, R | 1 |
| Laurin, J | 1 |
| Gervais, F | 1 |
| Tremblay, P | 1 |
| Melnikova, I | 1 |
| Santa-María, I | 1 |
| Hernández, F | 1 |
| Moreno, FJ | 1 |
| Avila, J | 1 |
| Sugimoto, H | 1 |
| Arai, H | 1 |
| Kobayashi, K | 1 |
| Ichimiya, Y | 1 |
| Kosaka, K | 1 |
| Iizuka, R | 1 |
| Boatell, ML | 1 |
| Bendahan, G | 1 |
| Mahy, N | 1 |
| Csernansky, JG | 1 |
| Bardgett, ME | 1 |
| Sheline, YI | 1 |
| Morris, JC | 1 |
| Olney, JW | 1 |
| Harkany, T | 1 |
| Abrahám, I | 1 |
| Timmerman, W | 1 |
| Laskay, G | 1 |
| Tóth, B | 1 |
| Sasvári, M | 1 |
| Kónya, C | 1 |
| Sebens, JB | 1 |
| Korf, J | 1 |
| Nyakas, C | 1 |
| Zarándi, M | 1 |
| Soós, K | 1 |
| Penke, B | 1 |
| Luiten, PG | 1 |
| Trabace, L | 1 |
| Cassano, T | 1 |
| Cagiano, R | 1 |
| Tattoli, M | 1 |
| Pietra, C | 1 |
| Steardo, L | 1 |
| Kendrick, KM | 1 |
| Cuomo, V | 1 |
| Lombardini, JB | 1 |
| Kowall, NW | 1 |
| Beal, MF | 2 |
| Pomara, N | 1 |
| Singh, R | 1 |
| Deptula, D | 1 |
| Chou, JC | 1 |
| Schwartz, MB | 1 |
| LeWitt, PA | 1 |
| Alom, J | 1 |
| Mahy, JN | 1 |
| Brandi, N | 1 |
| Tolosa, E | 1 |
| Ellison, DW | 1 |
| Mazurek, MF | 1 |
| Bird, ED | 1 |
| Martin, JB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Renji Alzheimer's Disease Neuroimaging Cohort Study[NCT05433363] | 60 participants (Anticipated) | Observational | 2022-02-14 | Enrolling by invitation | |||
| A Phase I, Single Centre, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics in Plasma and Urine of Multiple Ascending Doses of ALZ-801 in Healthy Elderly Subjects[NCT04157712] | Phase 1 | 48 participants (Actual) | Interventional | 2015-09-26 | Completed | ||
| Four-Period, Single-Dose, Sequential Study in Healthy Adults, to Assess Pharmacokinetics of ALZ-801 and Tramiprosate From ALZ-801 Prototype Tablets and Effect of Food on Bioavailability of ALZ-801 and Tramiprosate for Selected Prototype Tablet[NCT04585347] | Phase 1 | 12 participants (Actual) | Interventional | 2015-09-16 | Completed | ||
| A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's Disease[NCT03277573] | Phase 1 | 40 participants (Anticipated) | Interventional | 2017-07-21 | Active, not recruiting | ||
| Pre-Clinical Alzheimer's (ALZ) Diagnosis (PCD) = Optimum Outcomes (OO)[NCT02835716] | 150 participants (Anticipated) | Observational [Patient Registry] | 2016-09-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for taurine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antibodies, Monoclonal, Humanized; Drug Discovery; Humans; | 2020 |
Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antibodies, Monoclonal, Humanized; Humans; Pharmaceutical | 2020 |
Contributions of Mass Spectrometry to the Identification of Low Molecular Weight Molecules Able to Reduce the Toxicity of Amyloid-β Peptide to Cell Cultures and Transgenic Mouse Models of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line; Cell Survival; Disaccharides; Disease | 2019 |
Roles of taurine in cognitive function of physiology, pathologies and toxication.
Topics: Alzheimer Disease; Animals; Antioxidants; Cognition; Cognitive Dysfunction; Dietary Supplements; Fem | 2019 |
Structure and Function of Alzheimer's Amyloid βeta Proteins from Monomer to Fibrils: A Mini Review.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Antibodies, Monoclonal, Humanized; Clinical Trial | 2019 |
Aluminium in parenteral nutrition: a systematic review.
Topics: Aluminum; Alzheimer Disease; Bone Diseases, Metabolic; Deferoxamine; Dyslipidemias; Humans; Iron; Ke | 2013 |
Proteoglycans and glycosaminoglycans in misfolded proteins formation in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Clinical Trials as Topic; Glycosaminoglycans; Heparin, Low | 2014 |
[Progress in the development of anti-amyloid drugs for treatment of Alzheimer's disease.].
Topics: Alanine; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor | 2010 |
The potential protective effect of tramiprosate (homotaurine) against Alzheimer's disease: a review.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Clinical Trials as Topic; Humans; No | 2012 |
Tramiprosate.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition; Humans; Nootropic Agents; Randomized C | 2006 |
Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: part I.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Alzheimer Disease; Brain; Dopamine Agents; Humans; Mema | 2006 |
[New approaches for the development of anti-Alzheimer's disease drugs based on the cholinergic hypothesis and amyloid hypothesis].
Topics: Acetylcholine; Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein | 2008 |
Taurine - monograph.
Topics: Alcoholism; Alzheimer Disease; Animals; Cardiovascular Diseases; Cystic Fibrosis; Diabetes Mellitus; | 2001 |
Review: recent studies on taurine in the central nervous system.
Topics: Aging; Alzheimer Disease; Animals; Brain Ischemia; Central Nervous System; Female; Humans; Hypoxia, | 1992 |
8 trials available for taurine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Topics: Administration, Oral; Adult; Aged; Alzheimer Disease; Area Under Curve; Capsules; Dose-Response Rela | 2018 |
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Topics: Administration, Oral; Adult; Aged; Alzheimer Disease; Area Under Curve; Capsules; Dose-Response Rela | 2018 |
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Topics: Administration, Oral; Adult; Aged; Alzheimer Disease; Area Under Curve; Capsules; Dose-Response Rela | 2018 |
Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Topics: Administration, Oral; Adult; Aged; Alzheimer Disease; Area Under Curve; Capsules; Dose-Response Rela | 2018 |
Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Apolipoprotein E4; Cognition; Dose-Response Relation | 2017 |
Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Chromatography, Liquid; Cognition Di | 2018 |
Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid; Double-Blind Method; Female; GABA Agonists; Hum | 2009 |
Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cognition; Dose-Respo | 2009 |
Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cognition; Dose-Response Relations | 2009 |
Vagus nerve stimulation in patients with Alzheimer's disease: Additional follow-up results of a pilot study through 1 year.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cholinesterase Inhibi | 2006 |
A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Brain; Diarrhea; Dose-Response Re | 2006 |
39 other studies available for taurine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Taurine and Camel Milk Modulate Neurobehavioral and Biochemical Changes in Aluminum Chloride-Induced Alzheimer's Disease in Rats.
Topics: Acetylcholinesterase; Aluminum Chloride; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; C | 2021 |
A possible blood plasma biomarker for early-stage Alzheimer's disease.
Topics: Alzheimer Disease; Biomarkers; Clinical Trials, Phase II as Topic; Humans; Phosphates; Plasma; Tauri | 2022 |
IL-33 and IL-10 Serum Levels Increase in MCI Patients Following Homotaurine Treatment.
Topics: Alzheimer Disease; Cognitive Dysfunction; Cytokines; Humans; Interleukin-10; Interleukin-18; Interle | 2022 |
Investigation Covering the Effect of Boron plus Taurine Application on Protein Carbonyl and Advanced Oxidation Protein Products Levels in Experimental Alzheimer Model.
Topics: Advanced Oxidation Protein Products; Alzheimer Disease; Animals; Antioxidants; Boron; Neurodegenerat | 2023 |
Spatio-temporal metabolic rewiring in the brain of TgF344-AD rat model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Brain; Choline; Creatine; Disease Models, Animal; Disease Progression; G | 2022 |
Taurine and deferiprone against Al-linked apoptosis in rat hippocampus.
Topics: Aluminum; Alzheimer Disease; Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Chelating Ag | 2023 |
Taurine and deferiprone against Al-linked apoptosis in rat hippocampus.
Topics: Aluminum; Alzheimer Disease; Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Chelating Ag | 2023 |
Taurine and deferiprone against Al-linked apoptosis in rat hippocampus.
Topics: Aluminum; Alzheimer Disease; Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Chelating Ag | 2023 |
Taurine and deferiprone against Al-linked apoptosis in rat hippocampus.
Topics: Aluminum; Alzheimer Disease; Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Chelating Ag | 2023 |
UHPLC-Orbitrap-Fusion-TMS-Based Metabolomics Study of Phenylpropionamides in the Seed of Cannabis sativa L. against Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Bile Acids and Salts; Cannabis; Chromatography, High Pressure Liquid; Me | 2023 |
Effects of taurine on metal cations, transthyretin and LRP-1 in a rat model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Liver; Male; Metals; Prealbumin; Rats; Tau | 2023 |
Common Molecular Signatures Between Coronavirus Infection and Alzheimer's Disease Reveal Targets for Drug Development.
Topics: Alzheimer Disease; COVID-19; Drug Development; Gene Expression Profiling; Humans; MicroRNAs; Taurine | 2023 |
A diet rich in taurine, cysteine, folate, B
Topics: Alzheimer Disease; Animals; Betaine; Brain; Cysteine; Diet; Dietary Supplements; Folic Acid; Gases; | 2019 |
Dual targeting of cholinesterase and amyloid beta with pyridinium/isoquinolium derivatives.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Catalytic Domain; Cell Line | 2020 |
Cross-Interplay between Osmolytes and mTOR in Alzheimer's Disease Pathogenesis.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Autophagy; Humans; Taurine; TOR Serine-Threonine Kinases | 2020 |
Evaluation of the neuroprotective effect of taurine in Alzheimer's disease using functional molecular imaging.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Disease Models, Animal; Hippocampus; Human | 2020 |
9R, the cholinesterase and amyloid beta aggregation dual inhibitor, as a multifunctional agent to improve cognitive deficit and neuropathology in the triple-transgenic Alzheimer's disease mouse model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain Chemistry; Cholinesterase Inhibito | 2020 |
Curcumin and Homotaurine Suppress Amyloid-β
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Brain; Curcumin; Humans; Peptide Fragments; Tauri | 2021 |
Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Apolipoprotein E4; Dose-Response Relationship, Drug; Drug | 2017 |
Synergistic Inhibitory Effect of GQDs-Tramiprosate Covalent Binding on Amyloid Aggregation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloidogenic Proteins; Amyloidosis; Diabetes Mellitus, Ty | 2018 |
A longitudinal multimodal in vivo molecular imaging study of the 3xTg-AD mouse model shows progressive early hippocampal and taurine loss.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Biomarkers; Blood-Brain Barrier; Disease Models, | 2019 |
Taurine ameliorates neurobehavioral, neurochemical and immunohistochemical changes in sporadic dementia of Alzheimer's type (SDAT) caused by intracerebroventricular streptozotocin in rats.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Hippocampus; Immunohistochemistry; Infusions, Intr | 2013 |
Taurine attenuates amyloid β 1-42-induced mitochondrial dysfunction by activating of SIRT1 in SK-N-SH cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Calcium; Cell Line, Tumor; Humans; Mitochondria; Neurons; | 2014 |
Taurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Blotting, Western | 2014 |
Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy.
Topics: Acamprosate; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Apop | 2015 |
QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomers.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Carrier Proteins; Catechin; Disease Models, Anima | 2015 |
An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Aβ42 aggregates linked with Alzheimer's disease.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Animals; Animals, Genetically Modifie | 2016 |
Accuracy of cerebrospinal fluid Aβ1-42 measurements: evaluation of pre-analytical factors using a novel Elecsys immunosassay.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antibodies; Cryoprotective Agents; Freezing; Humans; Immun | 2017 |
Investigation of the noncovalent interactions between anti-amyloid agents and amyloid beta peptides by ESI-MS.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Peptides; Humans; Molecular Sequence Data; Mole | 2010 |
Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Alzheimer Disease; Amyloid beta-Protein Pr | 2004 |
Studies on protein and taurine in normal, senile and diabetic cataractous human lenses.
Topics: Adult; Alzheimer Disease; Cataract; Crystallins; Diabetes Mellitus; Female; Humans; Male; Proteins; | 2004 |
Therapies for Alzheimer's disease.
Topics: Alzheimer Disease; Alzheimer Vaccines; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; | 2007 |
Taurine, an inducer for tau polymerization and a weak inhibitor for amyloid-beta-peptide aggregation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Humans; Molecular Structure; Neurofibrillary Tangles; Plaq | 2007 |
A preliminary study of free amino acids in the postmortem temporal cortex from Alzheimer-type dementia patients.
Topics: Aged; Alzheimer Disease; Amino Acids; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Humans; Ki | 1984 |
Time-related cortical amino acid changes after basal forebrain lesion: a microdialysis study.
Topics: Alzheimer Disease; Amino Acids; Animals; Brain Diseases; Cerebral Cortex; Chromatography, High Press | 1995 |
CSF excitatory amino acids and severity of illness in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Glutamine; Humans; Middle Aged; Neuropsychological Tests; Se | 1996 |
beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Aspartic Acid; Astrocytes; Basal Nucleus of Meyne | 2000 |
Effects of ENA713 and CHF2819, two anti-Alzheimer's disease drugs, on rat amino acid levels.
Topics: Alzheimer Disease; Animals; Arginine; Aspartic Acid; Carbamates; Cholinesterase Inhibitors; Citrulli | 2001 |
Glutamate-, glutaminase-, and taurine-immunoreactive neurons develop neurofibrillary tangles in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Female; Glutamates; Glutamic Acid; Glutaminase; Hippocam | 1991 |
Glutamate and other CSF amino acids in Alzheimer's disease.
Topics: Age Factors; Alzheimer Disease; Amino Acids; Brain; Female; Glutamates; Humans; Male; Middle Aged; P | 1992 |
Cerebrospinal fluid taurine in Alzheimer's disease.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Female; Humans; Male; Middle Aged; Taurine | 1991 |
A postmortem study of amino acid neurotransmitters in Alzheimer's disease.
Topics: Aged; Aging; Alanine; Alzheimer Disease; Amino Acids; Aspartic Acid; Brain; gamma-Aminobutyric Acid; | 1986 |